Malin Johannesson

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease

Linda Söderberg, Malin Johannesson, Patrik Nygren et al. · Neurotherapeutics · 2022 · 387 citations · Full text

Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice

Veronica Lindström, Therese Fagerqvist, Eva Nordström et al. · Neurobiology of Disease · 2014 · 133 citations · Full text

Immunology, Pathology, α-Synuclein Protofibrils +3

Expression of 15-lipoxygenase type-1 in human mast cells

M. Gulliksson, Åsa Brunnström, Malin Johannesson et al. · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · 2007 · 62 citations

Inflammation, Molecular Physiology, Mast Cell Disorder +8

ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease

Eva Nordström, Fredrik Eriksson, Jessica Sigvardson et al. · Neurobiology of Disease · 2021 · 49 citations · Full text

Immunology, Neurochemical Biomarkers, Therapeutics +23

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities

Linda Söderberg, Malin Johannesson, Eleni Gkanatsiou et al. · Scientific Reports · 2024 · 45 citations · Full text